20-F: Evogene Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023

Evogene Ltd. released its 20-F annual report, detailing its financial performance and operational activities for the fiscal year ended December 31, 2023.

Summary

• Evogene Ltd., a computational biology company, has filed its 20-F annual report for the fiscal year ended December 31, 2023.
• The company focuses on revolutionizing life-science product discovery and development across various market segments, including human health, agriculture, and other industries.
• Evogene operates through subsidiaries like Biomica, AgPlenus, Lavie Bio, and Casterra, each targeting specific markets with computational biology-driven products.
• The company incurred operating losses of approximately $26.5 million in 2023, $26.9 million in 2022 and $31.0 million in 2021.
• As of December 31, 2023, the company had cash, cash equivalents, and short-term bank deposits of approximately $31.1 million.
• The company's strategy includes licensing its AI tech-engines and engaging in collaborative ventures with industry leaders.
• Evogene is emphasizing research and development efforts on MicroBoost AI and ChemPass AI.
• The company is subject to various government regulations and faces competition in its operating markets.
• Evogene is working to develop and commercialize novel ag-biological, ag-chemical, and seed-trait products.
• The company's medical cannabis activity exposes it to legal and reputational risks.
• Conditions in Israel, including the recent conflict, could adversely affect the company's business.
• The price of the company's ordinary shares may fluctuate significantly.
• The company believes it was a Passive Foreign Investment Company (PFIC) for U.S. tax purposes in 2023.
• The company is subject to evolving corporate governance and public disclosure regulations.
• The company is working to develop human microbiome-based therapeutic product candidates.
• The company is working to develop and commercialize castor seeds for industrial applications.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as new collaborations and grants, the company continues to experience operating losses and faces various risks and challenges.

Positives

• Lavie Bio entered a licensing agreement with Corteva Agriscience LLC, receiving an initial payment of approximately $5 million.
• Casterra signed a framework agreement with ENI Kenya B.V. for the sale of castor seeds for sustainable biofuel production, involving initial purchase orders of $9.1 million.
• Biomica closed a $20 million financing round led by Shanghai Healthcare Capital.
• AgPlenus entered into a licensing and collaboration agreement with Bayer AG for the development of a new sustainable weed control solution.
• Evogene's Ag-Seed Division was granted 1.2 million through a Horizon grant to develop high carbon dioxide assimilation and drought-tolerant oil-seed crops.

Negatives

• Evogene has a history of operating losses and negative cash flow.
• The company incurred operating losses of approximately $26.5 million in 2023.
• The dilution of equity holdings in subsidiary companies will likely negatively impact operational results.
• The company's medical cannabis activity exposes it to legal and reputational risks.
• The company believes it was a Passive Foreign Investment Company (PFIC) for U.S. tax purposes in 2023.

Risks

• The company may need substantial additional capital in the future, which may cause dilution to existing shareholders.
• Discoveries and product candidates may not achieve the desired effect required in order to create commercially-viable products.
• The product development cycle is lengthy and uncertain, and the company may never sell or earn royalties on the sale of commercial products based on its discoveries.
• The company depends on a few collaborators to develop and commercialize product candidates.
• The company is operating in multiple industries, each of which consists of multiple companies with much greater resources than it.
• Conditions in Israel could adversely affect the company's business, including the recent attack by Hamas and other terrorist organizations.
• Exchange rate fluctuations between the U.S. dollar and the NIS may negatively affect the company's financial results.
• The terms of Israeli government grants may require the company to satisfy specified conditions in order to manufacture products and transfer technologies supported by such grants outside of Israel.
• The price of the company's ordinary shares may fluctuate significantly, and there is no guarantee of a continuing public market to resell the shares.
• Any inability to meet the Nasdaq listing requirements may have an adverse effect on the company's share price and lead to delisting from Nasdaq.
• If the company fails to maintain effective internal control over financial reporting, the price of its ordinary shares may be adversely affected.

Future Outlook

The company expects to continue to develop its product pipelines and initiate new collaborations with an increased focus on strategic relationships for joint product development in 2024.

Industry Context

The report highlights Evogene's position in the competitive landscape of the agriculture, human health, and industrial applications markets, noting the presence of larger companies with greater resources.

Comparison to Industry Standards

• The report mentions the global crop protection chemicals market was estimated at approximately $88.2 billion in 2022 and is expected to grow to over $132 billion by 2032.
• The cancer immunotherapy market size was estimated at $85.6 billion in 2020 and is expected to reach a market size of $309.7 billion by 2030.
• The global IBD drug market size was valued at $21 billion in 2021, and is projected to reach $34.5 billion by 2031.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may be affected by cost-cutting measures and reductions in force.
• Customers may benefit from the development of new and improved products.
• Suppliers may be affected by changes in the company's operations and collaborations.
• Creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company expects to continue to develop its product pipelines and initiate new collaborations with an increased focus on strategic relationships for joint product development in 2024.
• The company plans to cease its activity in the medical cannabis field through Canonic.

Key Dates

Keywords

Evogene, financial report, computational biology, ag-biologicals, ag-chemicals, seed traits, human microbiome, medical cannabis, castor seeds, biomica, agplenus, lavie bio, casterra, revenue, operating loss, PFIC, Nasdaq